The Latin America, Middle East and Africa Muscle Relaxant Drugs Market would witness market growth of 6.2% CAGR during the forecast period (2023-2029).
The number of fibromyalgia (FM) research articles has significantly expanded over the last few decades. This increase may be attributed to heightened awareness and common interest among a number of stakeholders, including the pharmaceutical business, patient self-help organizations, clinicians, and researchers. In addition to encouraging research to understand the underlying pathophysiology better and enhance therapy, this designation of FM will also encourage using muscle relaxants to lessen the amount of discomfort experienced by FM patients.
The rising demand for muscle relaxant treatments in the cosmetic industry and increased online sales of these medications are the primary trends that can be seen in the market for these medications. Many retailers and pharmaceutical companies have made muscle relaxant medications accessible to the public online. Online retailing has been a significant trend in the market since it makes drugs more accessible, saves time, and is more convenient while offering cheaper pricing.
Israel's population is aging more quickly than the average, much like in many other countries throughout the world. The proportion of adults 65 and older has increased by 18 since 1950. The overall population of Israel is expected to reach 12.1 million by 2035, with seniors making up roughly 14% of the total, or 1.9 million people. Only 4% of people were 65 and older in 1948 when the State of Israel was established. Over time, there has been constant growth in this population. Life expectancy has risen by 1% annually since 1995, which is expected to continue. As muscle pain-related problems are more common in older people, demand is projected to rise, spurring market expansion in LAMEA.
The Brazil market dominated the LAMEA Muscle Relaxant Drugs Market by Country in 2022 thereby, achieving a market value of $81.5 Million by 2029. The Argentina market is showcasing a CAGR of 6.8% during (2023 - 2029). Additionally, The UAE market would register a CAGR of 5.9% during (2023 - 2029).
Based on Drug Type, the market is segmented into Skeletal, Neuromuscular Blocking Agents and Facial Muscle Relaxant Drugs. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Muscle Relaxant Drugs Market is Projected to reach USD 4.7 Billion by 2029, at a CAGR of 4.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amneal Pharmaceuticals, Inc., Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Mallinckrodt PLC, Teva Pharmaceuticals Industries Ltd., Eisai Co., Ltd., Endo International PLC, Vertical Pharmaceuticals, LLC, SteriMax Inc., and Metacel Pharmaceuticals, LLC.
By Drug Type
By Route of Administration
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
